Year: 2023

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonistInitiating in Q4 2023 a global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimabAnnounced positive top-line Phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP)Reiterating cash runway through year-end 2026 and updating expected year-end 2023 cash and investments of $400 to $410 millionSAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update. “We’ve made strong progress this quarter executing against our multi-year plan to develop best-in-class...

Quarterly revenue of $853 million; GAAP EPS of $1.39 and adjusted EPS of $1.97 DALLAS, Nov. 02, 2023 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2023 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q3 2023 % Change Q3 2022 YTD September 30, 2023 % Change YTD September 30, 2022Revenue $853.5 (25%) $2,971.0 (28%)Gross profit $289.5 (25%) $988.6 (26%)Net income $53.2 (42%) $198.2 (45%)GAAP diluted EPS $1.39 (34%) $4.99 (38%)Adjusted diluted EPS* $1.97 (23%) $6.86 (27%)Adjusted EBITDA* $133.7 (26%) $475.1 (29%)* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table...

JACKSONVILLE, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended September 30, 2023 and provided updated 2023 earnings guidance. For the three months ended September 30, 2023 and 2022, Net Income was $0.50 per diluted share and $0.51 per diluted share, respectively. Third Quarter 2023 HighlightsReported Nareit FFO of $1.02 per diluted share, which includes a $0.01 per diluted share impact for merger transition expense, and Core Operating Earnings of $0.97 per diluted share Raised 2023 full year Nareit FFO guidance to a range of $4.13 to $4.15 per diluted share and 2023 full year Core Operating Earnings guidance to a range of $3.93 to $3.95 per diluted share The midpoint of the updated 2023 Core Operating...

Raises Full-Year Outlook Given Strong Third Quarter Performance WESTPORT, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) — Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today its consolidated operating results for the three months ended September 30, 2023. “Our third quarter results were remarkably strong, driven by Lugano’s continued outperformance and the majority of our companies performing above expectations,” said Elias Sabo, CEO of Compass Diversified. “The consistent resilience of our results against a challenging economic backdrop reflects not only the diversification of our subsidiaries, but our ability to find strong businesses that produce above-trend growth. Given our strong performance, we remain confident that our diversified group of subsidiaries will continue...

Introduces Fiscal Year 2024 Revenue Guidance of $4.5 Billion to $4.8 Billion and Fiscal Year 2024 Adjusted EBITDA Guidance of $350 Million to $450 Million BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced its third quarter 2023 financial results. The Company also posted a third quarter 2023 business update and an earnings presentation on the Investor Relations section of its website at investors.draftkings.com. Third Quarter 2023 HighlightsFor the three months ended September 30, 2023, DraftKings reported revenue of $790 million, an increase of $288 million, or 57%, compared to $502 million during the same period in 2022 driven primarily by continued healthy customer engagement, efficient acquisition of new customers, the expansion of the Company’s Sportsbook...

Net sales of $2.254 billion, down 1.5% sequentially and up 8.7% from the year ago quarter. The midpoint of our guidance provided on August 3, 2023 was net sales of $2.266 billion. On a GAAP basis: gross profit of 67.8%; operating income of $885.0 million and 39.3% of net sales; record net income of $666.6 million; and record EPS of $1.21 per diluted share. Our guidance provided on August 3, 2023 was for GAAP EPS of $1.18 to $1.21 per diluted share. On a Non-GAAP basis: gross profit of 68.1%; operating income of $1.085 billion and 48.1% of net sales; net income of $889.3 million and EPS of $1.62 per diluted share. Our guidance provided on August 3, 2023 was for Non-GAAP EPS of $1.60 to $1.64 per diluted share. Returned approximately $562.5 million to shareholders in the September quarter through dividends of $222.7 million and the repurchase...

MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) today announced its operating results for the three and nine months ended September 30, 2023. “Our third quarter performance reflects the geographic and demographic quality of our portfolio. Our urban markets have outperformed, led by New York City, as demand and pricing are more stable and less impacted by the single-family home sales market,” commented President and Chief Executive Officer Christopher P. Marr. “As post-pandemic demand trends normalize and macroeconomic conditions remain volatile, our seasoned management team is maintaining our focus on maximizing revenues, controlling our costs, and providing outstanding customer service.” Key Highlights for the Third QuarterReported diluted earnings per share (“EPS”) attributable to the Company’s common...

Financial HighlightsNet (loss) income attributable to common shareholders for the third quarter 2023 of $(7.9) million, or $(0.09) per diluted share, compared to $11.3 million, or $0.13 per diluted share for the same period in 2022.Third quarter 2023 Operating funds from operations (“FFO”) per diluted share of $0.24.Same property net operating income (“NOI”) during the third quarter 2023 increased 2.6% compared to the same period in 2022, exceeding internal quarterly expectations.Operational HighlightsSigned 747,672 square feet in the third quarter 2023, representing the fifth consecutive quarter of leasing volume over 500,000 square feet and the highest quarterly amount since the first quarter 2010.Grew the signed not commenced rent and recovery income balance to $13.1 million as of September 30,...

Dallas, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) — Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $20.4 million, or $.18 per share, in the third quarter of 2023 compared to net income of $21.0 million, or $.18 per share, in the third quarter of 2022. For the first nine months of 2023, Kronos Worldwide reported a net loss of $43.8 million, or $.38 per share, compared to net income of $124.4 million, or $1.08 per share, in the first nine months of 2022. Net income decreased in the third quarter of 2023 as compared to the third quarter of 2022 primarily due to lower income from operations as a result of lower sales volumes and lower average TiO2 selling prices. Net income decreased in the first nine months of 2023 as compared to the first nine months of 2022 primarily due to lower income from operations as a result of...

Health Catalyst Q3 2023 Financial Highlights & Key ThemesNovember 2, 2023SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2023. “For the third quarter of 2023, I am pleased by our strong financial results, including total revenue of $73.8 million and Adjusted EBITDA of $2.0 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise our full year 2023 revenue guidance range and reiterate our full year 2023 Adjusted EBITDA guidance range. We are also encouraged by our bookings results through Q3 2023,...